Details of the Drug

General Information of Drug (ID: DMHPZ8G)

Drug Name
CD20-Specific CAR T Cells
Indication
Disease Entry ICD 11 Status REF
Chronic lymphocytic leukaemia 2A82.0 Phase 1/2 [1]
Follicular lymphoma 2A80 Phase 1/2 [1]
Large cell lymphoma 2A80.Z Phase 1/2 [1]
Lymphoma 2A80-2A86 Phase 1/2 [1]
Mantle cell lymphoma 2A85.5 Phase 1/2 [1]
Non-hodgkin lymphoma 2B33.5 Phase 1/2 [1]
⏷ Show the Full List of Indication(s)
Drug Type
CAR T Cell Therapy
Cross-matching ID
TTD ID
D0Q0RX
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN CAR-T-Cell-Therapy [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03277729) A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas